Developer docs
API playgroundTry for free, no card

Search company profiles

Lyell Immunopharma

Full company profile

uuid0000593

Namestring
Lyell Immunopharma
Legal namestring
Lyell Immunopharma, Inc.
Websiteurl
lyell.com
Company typeenum
Public
Founded yearint
2018
Descriptiontext

Lyell Immunopharma, Inc. (NASDAQ: LYEL) is a clinical-stage biotechnology company headquartered in South San Francisco, California, developing next-generation autologous CAR T-cell therapies for hematologic malignancies and solid tumors. The company was founded in 2018 by cell therapy pioneers Rick Klausner, Crystal Mackall, and Stan Riddell, and went public on NASDAQ in one of the largest biotech IPOs of its year. Lyell operates from three U.S. locations — South San Francisco (corporate headquarters), Seattle (clinical development, research, and process sciences), and Bothell, Washington (the LyFE Manufacturing Center, a wholly-owned cGMP cell therapy facility approved for clinical and commercial production with capacity for more than 1,200 patient products per year).

The company's pipeline is built around two lead autologous CAR T-cell product candidates supported by a proprietary cell therapy technology platform. The lead asset, ronde-cel (rondecabtagene autoleucel / LYL314), is a dual-targeting CD19/CD20 OR logic-gated CAR T-cell product candidate manufactured using a proprietary CD62L+ T-cell enrichment process. Ronde-cel is being evaluated in the PiNACLE single-arm pivotal trial (~120 patients, 3L+ aggressive large B-cell lymphoma) and the PiNACLE-H2H Phase 3 head-to-head randomized trial (~400 patients, 2L LBCL vs liso-cel or axi-cel) — the first randomized head-to-head comparison between CAR T-cell therapies. Phase 1/2 data has shown a 93% ORR and 76% CR rate with 18-month median PFS in 3L+ LBCL and a 97% manufacturing success rate. The second clinical asset, LYL273, is a guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate (with CD19 CAR and controlled cytokine release enhancements) in-licensed from Innovative Cellular Therapeutics in November 2025 for metastatic colorectal cancer, and is being evaluated in the Phase 1/2 CARABINER trial. Both assets hold FDA Fast Track designation, and ronde-cel additionally holds Regenerative Medicine Advanced Therapy (RMAT) designation.

Lyell is a pre-revenue company with no commercial product sales. Its business model is to advance clinical development, file a BLA for ronde-cel in the second half of 2027, and manufacture commercial supply in-house at the LyFE Manufacturing Center. Current operations are funded primarily through equity capital, including a ~$100 million two-tranche equity private placement closed in March 2026, against $134 million in annual R&D spending and a cash position of $254–280 million providing a runway into Q2 2027. The company serves the oncology and cell therapy community primarily through scientific conferences, peer-reviewed publications (including JAMA Oncology), its clinical trial sites in the U.S., Canada, and Australia, and direct engagement with treating centers and investigators.

Short descriptiontext

Lyell Immunopharma is a clinical-stage biotechnology company developing next-generation autologous CAR T-cell therapies for hematologic malignancies and solid tumors, using a proprietary CD62L+ enrichment manufacturing process and dual-targeting CAR constructs (ronde-cel for LBCL, LYL273 for metastatic colorectal cancer), with in-house cGMP manufacturing at its LyFE Manufacturing Center in Bothell, Washington.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
CAR T-cell therapy, cell therapy oncology, autologous cell therapy, cancer immunotherapy, clinical-stage biopharmaceutical
Industry2 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAKAFAD
Hematologic Oncology (Leukemia/Lymphoma/Myeloma)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell Therapy / CAR T-Cell Oncology
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1No Commercial Product Revenue
TypeSubscription Recurring
Description

Lyell Immunopharma is a clinical-stage biotech with no commercial product sales. The company generated $134 million in annual R&D spending, held $254 million in cash with a 23-month runway, and is dependent on equity financings (e.g., $100 million private placement) to sustain operations through pivotal data and potential BLA filing in 2027.

ainvest.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1LyFE Manufacturing Center
Description

Lyell's state-of-the-art cell therapy manufacturing facility located in Bothell, Washington; a registered trademark of Lyell Immunopharma, Inc.

lyell.com
+2 more records
Core offering1 text field

Lyell Immunopharma is a clinical-stage cell therapy company developing next-generation autologous CAR T-cell product candidates for hematologic malignancies and solid tumors. Its lead asset, ronde-cel (rondecabtagene autoleucel / LYL314), is a dual-targeting CD19/CD20 CAR T-cell therapy in pivotal development for large B-cell lymphoma; its second asset, LYL273, targets guanylyl cyclase-C for metastatic colorectal cancer. All candidates are manufactured at Lyell's wholly-owned LyFE Manufacturing Center in Bothell, Washington.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 93% overall response rate (ORR) and 76% complete response (CR) rate with 18-month median progression-free survival in third-line or later LBCL treatment (ronde-cel)
+6 more records
Product overview1 text field

Lyell Immunopharma is a clinical-stage cell therapy company, not a multi-product SaaS platform. Its offering is a focused pipeline of next-generation autologous CAR T-cell product candidates supported by an integrated discovery-to-manufacturing capability. The lead asset ronde-cel (also known as LYL314) is being advanced in two pivotal programs — the single-arm PiNACLE trial in third- or later-line aggressive large B-cell lymphoma (LBCL) and the randomized PiNACLE-H2H Phase 3 head-to-head trial versus liso-cel or axi-cel in the second-line LBCL setting. Its second clinical asset LYL273 is a GCC-targeted CAR T-cell product candidate (with CD19 CAR and controlled cytokine release enhancements) in Phase 1/2 development for metastatic colorectal cancer, with an additional undisclosed preclinical solid tumor program. All programs are powered by Lyell's proprietary cell therapy technology platform — featuring CD62L+ enrichment and dual-targeting CD19/CD20 logic-gated CAR constructs — and manufactured at Lyell's wholly-owned LyFE Manufacturing Center in Bothell, Washington, which at full capacity can produce more than 1,200 patient CAR T-cell products per year. Together, these named products, the underlying science platform, and the in-house manufacturing facility form a single integrated cell therapy offering rather than a platform-plus-modules architecture.

Product and service4 records
1Ronde-cel (rondecabtagene autoleucel / LYL314) — 3L+ LBCL Pivotal Program
CategoryClinical-stage autologous CAR T-cell therapy — hematologic malignancy
Description

Autologous dual-targeting CD19/CD20 CAR T-cell product candidate that recognizes and kills malignant B cells expressing either CD19 or CD20 antigens, manufactured using Lyell's proprietary CD62L+ enrichment process to enrich for naive and central memory T cells. Indicated for third- or later-line aggressive large B-cell lymphoma and currently in pivotal PiNACLE trial.

2Ronde-cel — 2L LBCL PiNACLE-H2H Phase 3 Program
CategoryClinical-stage autologous CAR T-cell therapy — hematologic malignancy
Description

Phase 3 head-to-head randomized controlled trial of ronde-cel versus investigator's choice of liso-cel or axi-cel for second-line treatment of relapsed/refractory aggressive large B-cell lymphoma; first randomized head-to-head comparison between CAR T-cell therapies; primary endpoint is event-free survival.

3LYL273
CategoryClinical-stage autologous CAR T-cell therapy — solid tumor
Description

Autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate in Phase 1/2 development (CARABINER trial) for relapsed/refractory metastatic colorectal cancer; expresses GCC, CD19, and GCC/CD19 doublet CAR T cells and is enhanced with controlled cytokine release to overcome solid tumor microenvironment barriers; in-licensed from Innovative Cellular Therapeutics.

4LyFE Manufacturing Center
CategoryIn-house cell therapy manufacturing capability
Description

Lyell's wholly-owned, state-of-the-art cell therapy manufacturing facility in Bothell, Washington, approved for clinical and commercial CAR T-cell production; provides supply chain control and the ability to rapidly incorporate manufacturing innovations into Lyell's product candidates.

Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeOthersAnnounced on2026-04-03
Description

Lyell Immunopharma filed a Form S-3 with the U.S. Securities and Exchange Commission on April 3, 2026 as a regulatory requirement for securities offerings.

2Innovative Cellular Therapeutics
Strategic tierFlagshipTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-11-10
Description

Lyell acquired exclusive global rights to LYL273, a next-generation CAR T-cell product candidate in clinical development for metastatic colorectal cancer, from Innovative Cellular Therapeutics. The Phase 1 U.S. trial demonstrated a 67% response rate. Lyell intends to advance LYL273's clinical development, with the FDA later granting Fast Track designation.

biospace.com
3ImmPACT Bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-10-01
Description

Lyell Immunopharma acquired ImmPACT Bio (a $30 million purchase reported as part of the October 16–31, 2024 oncology capital raises). Sumant Ramachandra, who served as CEO of ImmPACT Bio USA, joined Lyell's Board of Directors in October 2024 when ImmPACT was acquired by Lyell.

castleplacement.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Gilead's Kite Pharma subsidiary markets Yescarta and Tecartus — CD19-directed autologous CAR T-cell therapies approved in large B-cell lymphoma and mantle cell lymphoma, directly competing with ronde-cel in the same indication and patient setting.

2Bristol Myers Squibb (Juno Therapeutics / Celgene)
TypeDirect peer
Description

BMS markets Breyanzi (liso-cel) and Abecma, both autologous CAR T-cell therapies; liso-cel is an investigator's choice comparator in Lyell's PiNACLE-H2H Phase 3 trial, making BMS the most direct head-to-head competitor.

TypeBroad incumbent
Description

Novartis markets Kymriah, the first FDA-approved CD19 CAR T-cell therapy, used in pediatric ALL and adult DLBCL. As a large incumbent with established global manufacturing and commercialization, Novartis is a key competitive reference point for Lyell's heme pipeline.

TypeDirect peer
Description

Allogene is an allogeneic (off-the-shelf) CAR T-cell company developing CD19 and BCMA candidates, including the Cemacabtagene ansegedleucel program for LBCL. It overlaps directly with ronde-cel's hematologic indications while pursuing a fundamentally different allogeneic manufacturing model.

TypeDirect peer
Description

Nkarta is developing allogeneic and autologous CAR NK cell product candidates for hematologic malignancies and autoimmune disease, overlapping with Lyell's cell therapy modality and target indications. Lyell's incoming CMO David Shook was formerly Nkarta's CMO and Head of R&D.

TypeDirect peer
Description

Caribou is a clinical-stage allogeneic CAR T-cell company (CB-010, CB-011, CB-012) targeting CD19 and other antigens in B-cell malignancies. It is a direct peer in cell-based cancer therapy modality and B-cell lymphoma indication.

TypeEmerging player
Description

CRISPR Therapeutics, partnered with Vertex, developed Casgevy (exa-cel), the first FDA-approved CRISPR-based cell therapy. The company is also advancing allogeneic CAR T programs in oncology, making it an adjacent cell-therapy peer with overlapping platform science.

TypeEmerging player
Description

Iovance commercializes Amtagvi (lifileucel), a tumor-infiltrating lymphocyte (TIL) therapy approved for advanced melanoma, and is expanding in solid tumors. Comparable to Lyell as a clinical-to-commercial cell therapy company targeting solid tumor indications, though using a different cell type and modality.

TypeEmerging player
Description

Cellectis is a clinical-stage gene-editing company developing allogeneic CAR T-cell product candidates (including UCART19/ALLO-501) for hematologic malignancies. It is a peer in the CAR T-cell modality with overlapping heme targets but a distinct allogeneic platform.

TypeEmerging player
Description

Adaptimmune commercializes Tecelra (afami-cel), an engineered TCR-T cell therapy approved for synovial sarcoma, and is developing next-generation cell therapies for solid tumors. Overlaps with Lyell's solid tumor ambitions in autologous engineered T-cell therapy, though it uses TCR rather than CAR recognition.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment6 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Lyell Immunopharma

Cell Therapy / CAR T-Cell Oncologylyell.com

Lyell Immunopharma is a clinical-stage biotechnology company developing next-generation autologous CAR T-cell therapies for hematologic malignancies and solid tumors, using a proprietary CD62L+ enrichment manufacturing process and dual-targeting CAR constructs (ronde-cel for LBCL, LYL273 for metastatic colorectal cancer), with in-house cGMP manufacturing at its LyFE Manufacturing Center in Bothell, Washington.

What Lyell Immunopharma does

Lyell Immunopharma, Inc. (NASDAQ: LYEL) is a clinical-stage biotechnology company headquartered in South San Francisco, California, developing next-generation autologous CAR T-cell therapies for hematologic malignancies and solid tumors. The company was founded in 2018 by cell therapy pioneers Rick Klausner, Crystal Mackall, and Stan Riddell, and went public on NASDAQ in one of the largest biotech IPOs of its year. Lyell operates from three U.S. locations — South San Francisco (corporate headquarters), Seattle (clinical development, research, and process sciences), and Bothell, Washington (the LyFE Manufacturing Center, a wholly-owned cGMP cell therapy facility approved for clinical and commercial production with capacity for more than 1,200 patient products per year).

The company's pipeline is built around two lead autologous CAR T-cell product candidates supported by a proprietary cell therapy technology platform. The lead asset, ronde-cel (rondecabtagene autoleucel / LYL314), is a dual-targeting CD19/CD20 OR logic-gated CAR T-cell product candidate manufactured using a proprietary CD62L+ T-cell enrichment process. Ronde-cel is being evaluated in the PiNACLE single-arm pivotal trial (~120 patients, 3L+ aggressive large B-cell lymphoma) and the PiNACLE-H2H Phase 3 head-to-head randomized trial (~400 patients, 2L LBCL vs liso-cel or axi-cel) — the first randomized head-to-head comparison between CAR T-cell therapies. Phase 1/2 data has shown a 93% ORR and 76% CR rate with 18-month median PFS in 3L+ LBCL and a 97% manufacturing success rate. The second clinical asset, LYL273, is a guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate (with CD19 CAR and controlled cytokine release enhancements) in-licensed from Innovative Cellular Therapeutics in November 2025 for metastatic colorectal cancer, and is being evaluated in the Phase 1/2 CARABINER trial. Both assets hold FDA Fast Track designation, and ronde-cel additionally holds Regenerative Medicine Advanced Therapy (RMAT) designation.

Lyell is a pre-revenue company with no commercial product sales. Its business model is to advance clinical development, file a BLA for ronde-cel in the second half of 2027, and manufacture commercial supply in-house at the LyFE Manufacturing Center. Current operations are funded primarily through equity capital, including a ~$100 million two-tranche equity private placement closed in March 2026, against $134 million in annual R&D spending and a cash position of $254–280 million providing a runway into Q2 2027. The company serves the oncology and cell therapy community primarily through scientific conferences, peer-reviewed publications (including JAMA Oncology), its clinical trial sites in the U.S., Canada, and Australia, and direct engagement with treating centers and investigators.

Lyell Immunopharma firmographics

Firmographics
Name
Lyell Immunopharma
Legal name
Lyell Immunopharma, Inc.
Website
https://lyell.com
Company type
Public
Founded year
2018
Operating status
Operating
Headcount range
101–250 employees
Short description
Lyell Immunopharma is a clinical-stage biotechnology company developing next-generation autologous CAR T-cell therapies for hematologic malignancies and solid tumors, using a proprietary CD62L+ enrichment manufacturing process and dual-targeting CAR constructs (ronde-cel for LBCL, LYL273 for metastatic colorectal cancer), with in-house cGMP manufacturing at its LyFE Manufacturing Center in Bothell, Washington.
Ownership category
akta.pro rank

Lyell Immunopharma industry classification

Industry
Product category
Cell Therapy / CAR T-Cell Oncology
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAKAFAD
Hematologic Oncology (Leukemia/Lymphoma/Myeloma)

Keywords

  • CAR T-cell therapy
  • Cell therapy oncology
  • Autologous cell therapy
  • Cancer immunotherapy
  • Clinical-stage biopharmaceutical

Where Lyell Immunopharma is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Lyell Immunopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure

Revenue model

  1. No Commercial Product Revenue: Lyell Immunopharma is a clinical-stage biotech with no commercial product sales. The company generated $134 million in annual R&D spending, held $254 million in cash with a 23-month runway, and is dependent on equity financings (e.g., $100 million private placement) to sustain operations through pivotal data and potential BLA filing in 2027.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Lyell Immunopharma product offering

Product offering

Core offering

Lyell Immunopharma is a clinical-stage cell therapy company developing next-generation autologous CAR T-cell product candidates for hematologic malignancies and solid tumors. Its lead asset, ronde-cel (rondecabtagene autoleucel / LYL314), is a dual-targeting CD19/CD20 CAR T-cell therapy in pivotal development for large B-cell lymphoma; its second asset, LYL273, targets guanylyl cyclase-C for metastatic colorectal cancer. All candidates are manufactured at Lyell's wholly-owned LyFE Manufacturing Center in Bothell, Washington.

Product overview

Lyell Immunopharma is a clinical-stage cell therapy company, not a multi-product SaaS platform. Its offering is a focused pipeline of next-generation autologous CAR T-cell product candidates supported by an integrated discovery-to-manufacturing capability. The lead asset ronde-cel (also known as LYL314) is being advanced in two pivotal programs — the single-arm PiNACLE trial in third- or later-line aggressive large B-cell lymphoma (LBCL) and the randomized PiNACLE-H2H Phase 3 head-to-head trial versus liso-cel or axi-cel in the second-line LBCL setting. Its second clinical asset LYL273 is a GCC-targeted CAR T-cell product candidate (with CD19 CAR and controlled cytokine release enhancements) in Phase 1/2 development for metastatic colorectal cancer, with an additional undisclosed preclinical solid tumor program. All programs are powered by Lyell's proprietary cell therapy technology platform — featuring CD62L+ enrichment and dual-targeting CD19/CD20 logic-gated CAR constructs — and manufactured at Lyell's wholly-owned LyFE Manufacturing Center in Bothell, Washington, which at full capacity can produce more than 1,200 patient CAR T-cell products per year. Together, these named products, the underlying science platform, and the in-house manufacturing facility form a single integrated cell therapy offering rather than a platform-plus-modules architecture.

Differentiator

Problem solved

Functional benefit

Brands

  • LyFE Manufacturing Center: Lyell's state-of-the-art cell therapy manufacturing facility located in Bothell, Washington; a registered trademark of Lyell Immunopharma, Inc.
  • PiNACLE
  • PiNACLE-H2H

Products and services

  • Ronde-cel (rondecabtagene autoleucel / LYL314) — 3L+ LBCL Pivotal Program Autologous dual-targeting CD19/CD20 CAR T-cell product candidate that recognizes and kills malignant B cells expressing either CD19 or CD20 antigens, manufactured using Lyell's proprietary CD62L+ enrichment process to enrich for naive and central memory T cells. Indicated for third- or later-line aggressive large B-cell lymphoma and currently in pivotal PiNACLE trial.
  • Ronde-cel — 2L LBCL PiNACLE-H2H Phase 3 Program Phase 3 head-to-head randomized controlled trial of ronde-cel versus investigator's choice of liso-cel or axi-cel for second-line treatment of relapsed/refractory aggressive large B-cell lymphoma; first randomized head-to-head comparison between CAR T-cell therapies; primary endpoint is event-free survival.
  • LYL273 Autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate in Phase 1/2 development (CARABINER trial) for relapsed/refractory metastatic colorectal cancer; expresses GCC, CD19, and GCC/CD19 doublet CAR T cells and is enhanced with controlled cytokine release to overcome solid tumor microenvironment barriers; in-licensed from Innovative Cellular Therapeutics.
  • LyFE Manufacturing Center Lyell's wholly-owned, state-of-the-art cell therapy manufacturing facility in Bothell, Washington, approved for clinical and commercial CAR T-cell production; provides supply chain control and the ability to rapidly incorporate manufacturing innovations into Lyell's product candidates.

Quantifiable outcome

  • 93% overall response rate (ORR) and 76% complete response (CR) rate with 18-month median progression-free survival in third-line or later LBCL treatment (ronde-cel)
  • +6 more outcomes

Companies that use Lyell Immunopharma

Customer profile

Ideal customer profiles2 records

Lyell Immunopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Lyell Immunopharma partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and flagship.

  • SEC (Securities and Exchange Commission)coreOthers · 3 April 2026Lyell Immunopharma filed a Form S-3 with the U.S. Securities and Exchange Commission on April 3, 2026 as a regulatory requirement for securities offerings.
  • Innovative Cellular TherapeuticsflagshipOEM/ Whitelabel/ Licensing Partner · 10 November 2025Lyell acquired exclusive global rights to LYL273, a next-generation CAR T-cell product candidate in clinical development for metastatic colorectal cancer, from Innovative Cellular Therapeutics. The Phase 1 U.S. trial demonstrated a 67% response rate. Lyell intends to advance LYL273's clinical development, with the FDA later granting Fast Track designation.
  • ImmPACT BiocoreStrategic or Co-development Partner · 1 October 2024Lyell Immunopharma acquired ImmPACT Bio (a $30 million purchase reported as part of the October 16–31, 2024 oncology capital raises). Sumant Ramachandra, who served as CEO of ImmPACT Bio USA, joined Lyell's Board of Directors in October 2024 when ImmPACT was acquired by Lyell.

Scale indicators14 records

Recent moves6 records

Expansion highlights6 records

Lyell Immunopharma competitors and assessment

Company assessment

Direct peers

  • Gilead Sciences (Kite Pharma): Gilead's Kite Pharma subsidiary markets Yescarta and Tecartus — CD19-directed autologous CAR T-cell therapies approved in large B-cell lymphoma and mantle cell lymphoma, directly competing with ronde-cel in the same indication and patient setting.
  • Bristol Myers Squibb (Juno Therapeutics / Celgene): BMS markets Breyanzi (liso-cel) and Abecma, both autologous CAR T-cell therapies; liso-cel is an investigator's choice comparator in Lyell's PiNACLE-H2H Phase 3 trial, making BMS the most direct head-to-head competitor.
  • Allogene Therapeutics: Allogene is an allogeneic (off-the-shelf) CAR T-cell company developing CD19 and BCMA candidates, including the Cemacabtagene ansegedleucel program for LBCL. It overlaps directly with ronde-cel's hematologic indications while pursuing a fundamentally different allogeneic manufacturing model.
  • Nkarta: Nkarta is developing allogeneic and autologous CAR NK cell product candidates for hematologic malignancies and autoimmune disease, overlapping with Lyell's cell therapy modality and target indications. Lyell's incoming CMO David Shook was formerly Nkarta's CMO and Head of R&D.
  • Caribou Biosciences: Caribou is a clinical-stage allogeneic CAR T-cell company (CB-010, CB-011, CB-012) targeting CD19 and other antigens in B-cell malignancies. It is a direct peer in cell-based cancer therapy modality and B-cell lymphoma indication.

Broad incumbents

  • Novartis: Novartis markets Kymriah, the first FDA-approved CD19 CAR T-cell therapy, used in pediatric ALL and adult DLBCL. As a large incumbent with established global manufacturing and commercialization, Novartis is a key competitive reference point for Lyell's heme pipeline.

Emerging players

  • CRISPR Therapeutics: CRISPR Therapeutics, partnered with Vertex, developed Casgevy (exa-cel), the first FDA-approved CRISPR-based cell therapy. The company is also advancing allogeneic CAR T programs in oncology, making it an adjacent cell-therapy peer with overlapping platform science.
  • Iovance Biotherapeutics: Iovance commercializes Amtagvi (lifileucel), a tumor-infiltrating lymphocyte (TIL) therapy approved for advanced melanoma, and is expanding in solid tumors. Comparable to Lyell as a clinical-to-commercial cell therapy company targeting solid tumor indications, though using a different cell type and modality.
  • Cellectis: Cellectis is a clinical-stage gene-editing company developing allogeneic CAR T-cell product candidates (including UCART19/ALLO-501) for hematologic malignancies. It is a peer in the CAR T-cell modality with overlapping heme targets but a distinct allogeneic platform.
  • Adaptimmune Therapeutics: Adaptimmune commercializes Tecelra (afami-cel), an engineered TCR-T cell therapy approved for synovial sarcoma, and is developing next-generation cell therapies for solid tumors. Overlaps with Lyell's solid tumor ambitions in autologous engineered T-cell therapy, though it uses TCR rather than CAR recognition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Lyell Immunopharma social profiles

Digital presence

Lyell Immunopharma compliance and trust

Trust signal

Compliance2 records

Lyell Immunopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Lyell Immunopharma leadership team

Management profile

Number of profiles

Profiles15 records

Lyell Immunopharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Lyell Immunopharma funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Lyell Immunopharma M&A and investment

M&A and investment

M&A1 record

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lyell Immunopharma

What does Lyell Immunopharma do?

Lyell Immunopharma is a clinical-stage cell therapy company developing next-generation autologous CAR T-cell product candidates for hematologic malignancies and solid tumors. Its lead asset, ronde-cel (rondecabtagene autoleucel / LYL314), is a dual-targeting CD19/CD20 CAR T-cell therapy in pivotal development for large B-cell lymphoma; its second asset, LYL273, targets guanylyl cyclase-C for metastatic colorectal cancer. All candidates are manufactured at Lyell's wholly-owned LyFE Manufacturing Center in Bothell, Washington.

Is Lyell Immunopharma a public or private company?

Lyell Immunopharma is a public company. It is classified as public and is currently operating.

When was Lyell Immunopharma founded?

Lyell Immunopharma was founded in 2018. It employs 101 to 250 people.

Where is Lyell Immunopharma based?

Lyell Immunopharma is headquartered in South San Francisco, United States, in the North America region.

How does Lyell Immunopharma make money?

One revenue line is on record: no Commercial Product Revenue.

Who are Lyell Immunopharma's main competitors?

Direct peers on record are Gilead Sciences (Kite Pharma), Bristol Myers Squibb (Juno Therapeutics / Celgene), Allogene Therapeutics, Nkarta and Caribou Biosciences. Novartis is listed as a broad incumbent. Emerging players are CRISPR Therapeutics, Iovance Biotherapeutics, Cellectis and Adaptimmune Therapeutics.

Does Lyell Immunopharma have an API?

No public API is recorded for Lyell Immunopharma.

What industry is Lyell Immunopharma in?

Lyell Immunopharma's product category is Cell Therapy / CAR T-Cell Oncology. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAKAFAD, Hematologic Oncology (Leukemia/Lymphoma/Myeloma). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewHC Wainwright & Co. maintains Lyell Immunopharma at Buy, lowers price target to $39 from $45HC Wainwright & Co. maintained Lyell Immunopharma at Buy and lowered its price target to $39 from $45, a 13.3% decrease. The target implies an upside of 149.4% from the Nov 12 close of $15.64.Seeking AlphaLyell Immunopharma, Inc. (LYEL) Presents at Stifel 2026 Healthcare Conference 2026 TranscriptLyell Immunopharma presented at Stifel's 2026 Healthcare Conference, highlighting its lead CAR-T therapy ronde-cel for large B-cell lymphoma. The company is in two pivotal trials, including PiNACLE, with ASH data presentation and BLA submission planned for mid-next year.The future of tradingLyell Immunopharma, Inc. reports results for the quarter ended September 30 - Earnings SummaryLyell Immunopharma reported a quarterly adjusted loss of $1.86 per share for the quarter ended September 30, beating the analyst mean of $2.07. Revenue fell 80% to $3.00 thousand from a year ago, and the company posted a $45.53 million loss.The future of tradingLyell Immunopharma, Inc. <lyel.oq> expected to post a loss of $2.14 a share - Earnings PreviewLyell Immunopharma is expected to report a 79.2% revenue decline to $1.25 thousand from $6 thousand, with a loss of $2.14 per share. Analysts rate the stock a buy, with a median price target of $41.50, about 176.7% above the last closing price of $15.00.TradingViewLyell Immunopharma raises $80M in private placement; shares up 35%Lyell Immunopharma raised approximately $80 million through a private placement of common stock, issuing 7.43 million shares at $10.77 per share. The financing is expected to close around November 4, 2026, and extend the company's cash runway into 2028. Proceeds will primarily fund the development of rondecabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory large B-cell lymphoma.Investing.comBaird reiterates Lyell Immunopharma stock rating ahead of dataBaird reiterated an Outperform rating and $49 price target on Lyell Immunopharma, which trades at $10.98. The firm cites Lyell's ronde-cel CAR-T therapy as differentiated from Kite/Gilead's KITE-753, which faced a partial FDA hold. Baird awaits interim data from the PiNACLE study, scheduled for November 4.Business & FinancialLyell Immunopharma To Participate In November Investor EventsLyell Immunopharma will participate in three investor events in November 2026, including a Goldman Sachs RxChange fireside chat on its lymphoma CAR-T data. The company's pipeline includes next-generation CAR T-cell therapies for hematologic malignancies and solid tumors, with a manufacturing center expected to produce over 1,200 doses annually.MarketBeatLyell Immunopharma, Inc. (LYEL) - What Are Analysts Saying About This Stock?Lyell Immunopharma received an average analyst rating of Moderate Buy with a twelve-month target price of $40.86. The company reported Q2 EPS of -$1.92, beating the consensus of -$1.94, and revenue was $0.00 million. Analysts expect a fiscal-year EPS of -$7.16.Markets DailyAbsci (NASDAQ:ABSI) vs. Lyell Immunopharma (NASDAQ:LYEL) Critical ComparisonAbsci and Lyell Immunopharma are compared on institutional ownership, profitability, earnings, analyst ratings, and risk. Absci beats Lyell on 10 of 15 factors, but Lyell has higher upside potential. Absci's consensus target is $14.56, implying 58.56% upside.MarketBeatLyell Immunopharma (NASDAQ:LYEL) Stock Bumped Up to "Hold" by Wall Street ZenWall Street Zen upgraded Lyell Immunopharma from Sell to Hold, while other analysts have Buy, Hold, and Sell ratings. The stock opened at $9.39, with a consensus target price of $40.86 and a Moderate Buy rating. The company reported a loss of $1.92 EPS for the quarter.